sorafenib (Nexavar)

following a full submission assessed under the end of life and ultra-orphan processes

sorafenib (Nexavar®) is accepted for use within NHS Scotland.

Indication under review: treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.

Treatment with sorafenib demonstrated a significant, clinically relevant five-month improvement in median progression free survival compared with placebo in patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sorafenib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.